Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
enVVeno Medical Corp (NVNO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: NVNO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -33.35% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 51.56M USD | Price to earnings Ratio - | 1Y Target Price 16.5 |
Price to earnings Ratio - | 1Y Target Price 16.5 | ||
Volume (30-day avg) 91944 | Beta 1.38 | 52 Weeks Range 2.45 - 6.48 | Updated Date 03/27/2025 |
52 Weeks Range 2.45 - 6.48 | Updated Date 03/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.27 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-02-26 | When After Market | Estimate -0.35 | Actual -0.3 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -31.82% | Return on Equity (TTM) -49.39% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 8765249 | Price to Sales(TTM) - |
Enterprise Value 8765249 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.87 | Shares Outstanding 17535900 | Shares Floating 17374493 |
Shares Outstanding 17535900 | Shares Floating 17374493 | ||
Percent Insiders 0.92 | Percent Institutions 24.38 |
Analyst Ratings
Rating 5 | Target Price 18 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
enVVeno Medical Corp
Company Overview
History and Background
enVVeno Medical Corp. (NVNO) is a medical device company focused on developing and commercializing innovative solutions for the treatment of chronic venous disease. Founded in 2018, NVNO has been focused on bringing their VenoValve to market.
Core Business Areas
- Chronic Venous Disease (CVD) Solutions: Development and commercialization of the VenoValve for deep venous disease (DVD). Focused on improving the standard of care.
Leadership and Structure
The leadership team includes the CEO, President and other key executives overseeing R&D, operations, and finance. NVNO operates with a relatively small team and utilizes consultants and contractors.
Top Products and Market Share
Key Offerings
- VenoValve: The VenoValve is an implantable venous valve designed to improve venous blood flow in patients with deep venous disease. The company has not yet commercially launched, so there is no market share data or revenue. Competitors include existing conservative treatments (compression therapy) and potential future technologies addressing venous insufficiency. There are currently no readily available, directly competing implantable venous valves with robust clinical data.
Market Dynamics
Industry Overview
The market for venous disease treatment is substantial and growing due to the aging population and increasing prevalence of risk factors. Innovation in this space is welcomed as current treatments have major shortcomings.
Positioning
enVVeno Medical Corp. is positioned as an innovator in the venous disease space, aiming to offer a more effective and less invasive treatment option compared to existing methods.
Total Addressable Market (TAM)
The TAM for chronic venous disease is estimated to be in the billions of dollars. enVVeno Medical Corp is targeting a segment of this market, specifically patients with severe deep venous disease. Market reports estimate a TAM of approximately $2 billion, depending on indication and geography.
Upturn SWOT Analysis
Strengths
- Innovative technology with the potential to improve patient outcomes
- Focus on a large and underserved market
- Intellectual property protection for the VenoValve
Weaknesses
- Limited financial resources
- Dependence on successful clinical trial outcomes
- Not yet commercially launched and no revenue generated
Opportunities
- Expansion into new markets
- Partnerships with larger medical device companies
- Positive clinical trial results leading to regulatory approval
Threats
- Competition from established medical device companies
- Unsuccessful clinical trials
- Regulatory hurdles and delays
Competitors and Market Share
Key Competitors
- BSX
- EV3
- MDTC
Competitive Landscape
enVVeno Medical Corp. is competing in a market dominated by larger medical device companies. Their competitive advantage lies in their innovative technology and focus on a specific niche within the venous disease market.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is defined by advancement of clinical trials rather than product sales.
Future Projections: Future growth is heavily dependent on the successful completion of clinical trials, regulatory approval, and commercial launch of the VenoValve. Analyst estimates are difficult to ascertain given early state.
Recent Initiatives: Recent initiatives include ongoing clinical trials for the VenoValve, regulatory interactions, and securing additional funding.
Summary
enVVeno Medical Corp. is a development stage company with a novel device in a large, underserved market. Its strength lies in its innovative approach, but its weakness is its limited resources and dependence on future clinical trial success. Successful trials, regulatory approval and ability to launch a product are what the company needs to concentrate on and look out for to survive and grow.
Similar Companies
- BSX
- MDTC
- ABT
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Company Website
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. The information provided is subject to change. All financial metrics are approximations.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About enVVeno Medical Corp
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2018-05-31 | CEO & Director Mr. Robert A. Berman | ||
Sector Healthcare | Industry Medical Devices | Full time employees 37 | Website https://www.envveno.com |
Full time employees 37 | Website https://www.envveno.com | ||
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.